

СПИСЪК НА ТРУДОВЕТЕ
на чл.-кор. проф. дбн Илга Константинова Пъжева
за участие в конкурса за избор на академици на БАН - 2021

Трудовете са групирани както следва:

- I.** Публикации в списания с импакт-фактор (IF): **78**
- II.** Публикации в списания и тематични поредици със SCImago Journal Rank (SJR): **6**
- III.** Публикации в рецензирани периодични издания без IF и SJR: **22**
- IV.** Публикации в рецензирани тематични поредици, книги и сборници от национални и международни научни форуми: **24**
- V.** Глави от книги: **8** (в т.ч. 3 със SJR)
- VI.** Дисертации: **2**
- VII.** Редакции на книги (съставителство): **3**
- VIII.** Други трудове, в т.ч. с публицистичен характер: **12**

I. Публикации в списания с импакт-фактор (IF):

Статии на английски език (в хронологичен ред):

1. **Pajeva, I.K.**, Z.C.Lateva, and G.V.Dimitrov. BACOMP - Database of Bioactive Compounds for Structure - Activity Relationship, *Int. J. Bio-Med.Comput.*, **1986**, 18, 7-24.
IF=0.740 (1992)
2. **Pajeva, I.**, E.Golovinsky. Substructural Analysis of Antineoplastic Drugs in respect of *in Vivo* Tumor Models, *Quant.Struct.-Act.Relat.*, **1990**, 9, 216-222.
IF=1.528 (1992)
3. **Pajeva, I.**, I. Manolov, E. Golovinsky. Structure-Activity Relationship Investigation of Bis(2-Chloroethyl)- aminoethyl Esters of Some Carboxylic Acids, *Pharmazie*, **1990**, 45, 361-363.
IF=0.309 (1992)
4. Dimitrov,G.V.,N.A.Dimitrova, **I.K. Pajeva**. The threshold stimulation and accomodation of a Hodgkin-Huxley axon, *Gen.Physiol.Biophys.*, **1992**, 11, 59-68.
IF=0.573 (1992)
5. **Pajeva, I.K.**, D.K.Todorov. Studies of Doxorubicin in model membranes: relation to the mechanism of action and multidrug resistance, *Compt. rend. Acad. bulg. Sci.*, **1995**, 48 (11-12), 159-162.
IF =0.082 (1994)
6. **Pajeva, I.K.**, M.Wiese, H.-P.Cordes, J.K.Seydel. Membrane interactions of some catamphiphilic drugs and relation to their multidrug resistance reversing ability, *J.Cancer Res.Clin.Onc.*, **1996**, 122 (1), 27-40.
IF=1.093 (1996)
7. **Pajeva, I.K.**, M.Wiese. QSAR and molecular modelling study of multidrug resistance modifiers, *Quant. Struct.-Act. Relat.*, **1997**, 16 (1), 1-10.
IF=1.967 (1998)
8. Wiese, M., **I.K.Pajeva**: Molecular modeling study of the multidrug resistance modifiers cis- and trans-flupentixol, *Pharmazie*, **1997**, 52 (9), 679-685.
IF=0.419 (1998)
9. **Pajeva, I.K.**, D.K.Todorov: Study of Thaliblastine in model membranes: relation to mechanism of action and multidrug resistance, *Compt. rend. Acad. bulg. Sci.*, 50(2), **1997**, 69-72.
IF =0.082 (1994)
10. Timcheva, C., **I.Pajeva**, D.Todorov: Calcium channel blockers verapamil and diltiazem as modulators of multidrug resistance in tumours, *Compt. rend. Acad. bulg. Sci.*, **1997**, 50 (5) 137-140.
IF =0.082 (1994)
11. Naydenova Z.L., K. Grancharov, D. Alargov, E.Golovinsky, I. Stanoeva, L. Shalamanova,

- I.Pajeva:** Inhibition of UDP-glucuronosyltransferase by 5'-O-amino acid and oligopeptide derivatives of uridine: structure-activity relationships, *Zeitschrift für Naturforschung*, **1998**, 53c, 173-181.
IF= 0.839 (1998)
12. **Pajeva, I.K.**, M.Wiese: Molecular modeling of phenothiazines and related drugs as multidrug resistance modifiers: a comparative molecular field analysis study, *J. Med. Chem.*, **1998**, 41, 1815-1826.
IF= 3.739 (1998)
 13. **Pajeva, I.K.**, M.Wiese: A comparative molecular field analysis of propafenone-type modulators of cancer multidrug resistance, *Quant. Struct.-Act. Relat.*, **1998**, 17, 301-312.
IF=1.967 (1998)
 14. Todorov, D.K., M.V. Ilarionova, K.B. Timcheva, **I.K.Pajeva**: Antitumor activity of a *Dionaea Muscipula* E.preparation *Carnivora*□ new in vitro and in vivo on animal and human tumors, sensitive and resistant to antitumor drugs, *Biotechnol. Biotechn. Eq.*, 12(2), **1998**, 61-66.
IF= 0.029 (2002)
 15. **Pajeva, I.**, M. Wiese. Interpretation of CoMFA results - a probe set study using hydrophobic fields. *Quant. Struct.-Act. Relat.*, 18 (4), **1999**, 369-379.
IF=1.803 (1999)
 16. Todorov, D.K., M. V. Ilarionova, **I. Pajeva**. Effectiveness of a *Dionaea Muscipula* E.preparation *Carnivora*□ on antitumor drug-resistant tumour cells, *Compt. rend. Acad. bulg. Sci.*, 53 (1), **2000**, 129-132.
IF =0.082 (1994)
 17. Wiese, M., **I. Pajeva**. Structure-activity relationships of multidrug resistance reversers, *Curr. Med. Chem.*, **2001**, 8, 685-713.
IF=5.760 (2001)
 18. **Pajeva, I.K.**, M. Wiese. Human P-glycoprotein pseudoreceptor modeling: 3D-QSAR study of thioxanthene type multidrug resistance modulators, *Quant. Str.-Act. Relat.*, **2001**, 20, 130-138.
IF =1.414 (2001)
 19. **Pajeva, I.K.**, M. Wiese. Multidrug resistance related drugs: estimation of hydrophobicity as a space directed molecular property, *Compt. rend. Acad. bulg. Sci.*, **2001**, Tome 54, 11, 81-84.
IF =0.082 (1994)
 20. Tsakovska, I.M., **I.K.Pajeva**. Molecular modeling of triazine type MDR modulators using CoMFA and CoMSIA, *SAR and QSAR in Environmental Research*, **2002**, 13(2), 1-12.
IF=1.082 (2002)
 21. Lesigiarska I., **I. Pajeva**, S. Yanev. QSAR and 3D QSAR analysis of a series of xanthates as inhibitors and inactivators of cytochrome P-450 2B1, *Xenobiotica*, **2002**, 32 (16), 1063-1077.
IF=1.919 (2002)
 22. **Pajeva, I.K.**, M. Wiese. Pharmacophore model of drugs involved in P-glycoprotein multidrug resistance: explanation of structural variety (Hypothesis), *J. Med. Chem.*, **2002**, 45 (26), 5671-86.
IF=4.566 (2002)
 23. Tsakovska, I., M. Wiese, **I.Pajeva**. Molecular modeling of phenothiazines and structurally related multidrug resistance modulators: comparative study in human and animal tumor cell lines, *Biotechnol. Biotechn. Eq.*, **2003**, 17 (2), 163-169.
IF=0.055 (2003)
 24. **Pajeva I.**, D.K. Todorov, J.K. Seydel. Membrane effects of the antitumor drugs doxorubicin and thaliblastine: comparison to multidrug resistance modulators verapamil and trans-flupentixol, *Europ. J. Pharm. Sci.*, **2004**, 21(2-3), 243-250.
IF= 1.949 (2004)
 25. **Pajeva, I.K.**, C. Globisch, M. Wiese. Structure-Function Relationships of Multidrug Resistance P-glycoprotein, *J. Med. Chem.*, **2004**, 47 (10), 2523-2533.
IF= 5.076 (2004)
 26. **Pajeva, I.K.**, J.K. Seydel, D. K. Todorov. Interactions of the anticancer drugs doxorubicin and thaliblastine with model membranes and their relation to multidrug resistance, *Biotechnol. Biotechn. Eq.*, **2004**, 18 (1), 132-139.
IF=0.055 (2003)

27. Lessigiarska, I., **I. Pajeva**, M.T.D Cronin, A.P Worth. 3D SAR and QSAR investigation of blood-brain barrier penetration of chemical compounds, *SAR QSAR Environ. Res.*, **2005**, 16, 79-91.
IF=1.753 (2005)
28. Bogdanova S., **I. Pajeva**, P. Nikolova, I. Tsakovska, B. Müller. Interactions of poly (vinylpyrrolidone) with ibuprofen and naproxen: experimental and modeling studies, *Pharmaceut. Res.*, **2005**, 22 (5), 806-815.
IF= 2.752 (2005)
29. Lessigiarska, I., A. Nankov, A. Bocheva, **I. Pajeva**, A. Bijev. 3D-QSAR and preliminary evaluation of anti-inflammatory activity of series of N-pyrrolylcarboxylic acids, *Farmaco*, **2005**, 60(3), 209-218.
IF = 0.790 (2002)
30. **Pajeva, I.**, C. Globisch, R. Fleischer, I. Tsakovska, M. Wiese. Molecular modeling of P-glycoprotein and related drugs, *Med. Chem. Res.*, **2005**, 14(2), 106-117.
IF = 0.286 (2005)
31. Globisch, C, **I. K. Pajeva**, M. Wiese. Structure-Activity Relationships of a Series of Tariquidar Analogs as Multidrug Resistance Modulators, *Bioorg. Med. Chem.*, **2006**, 14(5), 1588-1598.
IF= 2.624 (2006)
32. Pinto-Bazurko M.M., I. Tsakovska, **I. Pajeva**. QSAR and 3D QSAR of inhibitors of the epidermal growth factor receptor, *Int. J. Quant. Chem.*, **2006**, 106 (3), 1432-1444.
IF=1.182 (2006)
33. Tsakovska I., **I. Pajeva**. Phenothiazines and structurally related compounds as modulators of cancer multidrug resistance. *Curr Drug Targets*, 7, **2006**, 1123-1134.
IF= 4.274 (2006)
34. Mueller, H., W. Klinkhammer, C. Globisch, M. Kassack, **I. Pajeva**, M. Wiese: New functional assay of P-glycoprotein activity using Hoechst 33342. *Bioorg. Med. Chem.*, **2007**, 15, 7470-7479.
IF= 2.662 (2007)
35. Globisch, C., **I. Pajeva**, M. Wiese: Identification of putative binding sites of P-glycoprotein based on its homology model, *ChemMedChem.*, **2008**, 3(2), 280-295.
IF=3.150 (2008)
36. Mueller, H., **I. Pajeva**, C. Globisch, M. Wiese. Functional assay and structure-activity relationships of new 3rd generation P-glycoprotein inhibitors. *Bioorg. Med. Chem.*, **2008**, 16, 2456-2470.
IF= 3.075 (2008)
37. Pencheva, T. D. Lagorce, **I. Pajeva**, B. O. Villoutreix, M.A. Miteva. AMMOS: Automated Molecular Mechanics Optimization tool for in silico Screening, *BMC Bioinformatics*, **2008**, 9, 438-452.
IF=3.781 (2008)
38. Fratev, F., S.O. Jonsdottir, E. Mihaylova, **I. Pajeva**. Molecular basis of inactive B-RAF(WT) and B-RAF(V600E) ligand inhibition, selectivity and conformational stability: an *in silico* study. *Mol. Pharmaceutics*, **2009**, 6(1), 144-157.
IF=5.408 (2009)
39. Klinkhammer W., H. Müller, **I. K. Pajeva**, M. Wiese. Synthesis and biological evaluation of a small molecule library of multidrug resistance modulators, *Bioorg. Med. Chem.*, **2009**, 17(6), 2524-2535.
IF = 2.822 (2009)
40. Tsekova, D.S., E. Ts. Makakova, P. S. Alov, G. A. Gorneva, **I. K. Pajeva**, L. P. Tancheva, V. V. Petkov, A. R. Surleva, B. Escuder, J. F. Miravet, E. Katz. Structure-activity relationships of new L-valine derivatives with neuropharmacological effects. *Bulgarian Chemical Communications*, **2009**, 41(2), 133-138.
IF = 0.156 (2009)
41. **Pajeva, I.**, M. Wiese. Structure-activity relationships of a series of tariquidar analogs as multidrug resistance modulators. *The AAPS Journal*, **2009**, 11 (3), 435-444.
IF = 3.540 (2009)

42. **Pajeva, I. K.** Book review of "Structural Bioinformatics: An Algorithmic Approach" by Forbes J. Burkowski, *BioMedical Engineering on Line*, **2009**, 8-14.
IF=1.639 (2009)
43. **Pajeva, I. K.**, C. Globisch, M. Wiese. Combined pharmacophore modeling, docking and 3D QSAR study of ABCB1 and ABCC1 transporter inhibitors. *ChemMedChem*, **2009**, 4 (11), 1883-1896.
IF = 3.232 (2009)
44. **Pajeva, I. K.**, C. Globisch, M. Wiese. Comparison of the inward- and outward-open homology models and ligand binding of human P-glycoprotein. *FEBS J.*, **2009**, 276 (23), 7016–7026.
IF = 3.042 (2009)
- 44a. Published also in: *Virtual Issue Ion Channels and Transporters of FEBS journal*, **2010**
45. Pencheva T, O.S, Soumana, **I. Pajeva** , M.A. Miteva. Post-docking virtual screening of diverse binding pockets: Comparative study using DOCK, AMMOS, X-Score and FRED scoring functions. *Eur J Med Chem.*, **2010**, 45, 2622–2628.
IF=3.193 (2010)
46. Tsakovska, I., **I. Pajeva**, P. Alov, A. Worth. Recent advances in the molecular modelling of estrogen receptor-mediated toxicity. *Adv Protein Chem Struct Biol.* **2011**, 85, 217-251.
IF=1.833 (2011)
47. Pick, A., H. Müller, R. Mayer, B. Haenisch, **I.K. Pajeva**, M. Weight, H. Bönisch, C. E. Müller, M. Wiese. Structure-Activity Relationships of Flavonoids ss Inhibitors of Breast Cancer Resistance Protein (BCRP). *Bioorg. Med. Chem.*, **2011**, 19(6), 2090-2102.
IF=2.921 (2011)
48. Lessigiarska I., **I. Pajeva**, P. Prodanova, M. Georgieva, A. Bijev. Structure-activity relationships of pyrrole hydrazones as new anti-tuberculosis agents. *Medicinal Chemistry*, **2012**, 8 (3), 462-473.
IF=1.373 (2012)
49. Jereva D., **I. Pajeva**, T. Pencheva. Data extraction module – a supplementary tool for AMMOS_ ProtLig software package. *Comput. Math. Appl.*, **2012**, 64 (3), 266-271.
IF=2.069 (2012)
50. Pencheva T., D. Jereva, M. Miteva, **I. Pajeva**. Post-docking Optimization and Analysis of Protein-Ligand Interactions of Estrogen Receptor Alpha using AMMOS Software. *Current Computer-Aided Drug Design*, **2013**, 9 (1), 83-94.
IF=1.942 (2013)
51. Fratev F, SO Jónsdóttir, **I. Pajeva**. Structural insight into the UNC-45-Myosin complex. *Proteins-Structure Function and Bioinformatics*, **2013**, 81(7), 1212-1221.
IF=2.921 (2013)
52. **Pajeva I.** , M. Hanl, M. Wiese. Protein contacts and ligand binding in the inward-facing model of human P-glycoprotein, *ChemMedChem.*, **2013**, 8 (5), 748–762.
IF=3.046 (2013)
53. **Pajeva I.**, K. Sterz, K. Steggemann, F. Marighetti, M. Christlieb, M. Wiese. Interactions of the multidrug resistance modulators tariquidar and elacridar and their analogs with P-glycoprotein. *ChemMedChem.*, **2013**, 8 (10), 1701–1713.
IF= 3.046 (2013)
54. Al Sharif M., P. Alov, V. Vitcheva, I. Pajeva, I. Tsakovska. Modes-of-action related to repeated dose toxicity: tissue-specific biological roles of PPAR γ ligand-dependent dysregulation in nonalcoholic fatty liver disease, *PPAR Research*, **2014**, Article ID 432647, 13 pages.
IF=2.509 (2014)
55. Wiese M., **I. Pajeva**. HAGE, the helicase antigen as a biomarker for breast cancer prognosis (WO2013144616). *Expert Opin. Ther. Pat.*, **2014**, 24(6), 723-725.
IF=4.297(2014)
56. Fratev F.; E. Mihaylova; **I. Pajeva**. Combination of genetic screen and molecular dynamics as a useful tool for identification of diseases-related mutations: ZASP PDZ domain G54S mutation

case. *J. Chem. Inf. Model.*, **2014**, 54(5), 1524-1536.

IF=3.738 (2014)

57. Tsakovska I., M. Al Sharif, P. Alov, A. Diukendjieva, E. Fioravanzo, M.T.D. Cronin, **I.K. Pajeva**. Molecular modelling study of PPAR γ receptor in relation to the mode of action / adverse outcome pathway framework for liver steatosis. *Int. J. Mol. Sci.*, **2014**, 15, 7651-7666.

IF=2.862 (2014)

58. Tzvetkov N.T., **I.K. Pajeva**. Binding and interactions of a novel potent indole-5-carboxamide MAO-B inhibitor. *Compt. rend. Acad. bulg. Sci.*, **2014**, Tom 67, No.7, 937-942.

IF=0.307 (2014)

59. Alov O., I. Tsakovska, **I. Pajeva**. Computational Studies of Free Radical-Scavenging Properties of Phenolic Compounds. *Current Topics in Medicinal Chemistry*, **2015**, 15(2), 85-104.

IF=2.900 (2015)

60. Fratev, F., I. Tsakovska, M. Al Sharif, E. Mihaylova, **I. Pajeva**. Structural and Dynamical Insight into PPAR γ Antagonism: *In Silico* Study of the Ligand-Receptor Interactions of Non-Covalent Antagonists. *Int. J. Mol. Sci.* **2015**, 16 (7), 15405-15424.

IF=3.257 (2015)

61. Alov, P., I. Tsakovska, **I. Pajeva**. Quantitative structure-property relationship modelling of antiradical properties of natural polyphenols using EVA vector descriptor approach. *Comptes rendus de l'Academie bulgare des Sciences*, 69 (9), **2016**, 1145-1152.

IF=0.251 (2016)

62. Diukendjieva A., M. Al Sharif, P. Alov, T. Pencheva, I. Tsakovska, **I. Pajeva**. ADME/Tox Properties and Biochemical interactions of Silybin Congeners: *In Silico* Study. *Natural Product Communications*, **2017**, 12 (2), 175-178.

IF = 0.809 (2017)

63. Al Sharif M., I. Tsakovska, **I. Pajeva**, P. Alov, E. Fioravanzo, A. Bassan, S. Kovarich, C. Yang, A. Mostrag-Szlichtyng, V. Vitcheva, A. P. Worth, A. N. Richarz, M.T. D. Cronin. The Application of Molecular Modelling in the Safety Assessment of Chemicals: A Case Study on Ligand-Dependent PPAR γ Dysregulation, *Toxicology*, **2017**, 392, 140-154. DOI:10.1016/j.tox.2016.01.009

IF=3.265 (2017)

64. Jereva, D., F. Fratev, I. Tsakovska, P. Alov, T. Pencheva, **I. Pajeva**. Molecular Dynamics Simulation of the Human Estrogen Receptor Alpha: Contribution to the Pharmacophore of the Agonists. *Mathematics and Computers in Simulation*, **2017**, 133 (C), 124-134. DOI:10.1016/j.matcom.2015.07.003

IF=1.476 (2017)

65. Labbé, C., T. Pencheva, D. Jereva, D. Desvillechabrol, J. Becot, B.O. Villoutreix, **I. Pajeva**, M. Miteva. AMMOS2: a web server for protein-ligand-water complexes refinement via molecular mechanics, *Nucleic Acids Research*, **2017**, 45 (W1), W350-W355. DOI:10.1093/nar/gkx397

IF = 11.561 (2017)

66. Tsakovska I., **I. Pajeva**, M. Al Sharif, P. Alov, E. Fioravanzo, S. Kovarich, A. P. Worth, A. Richarz, C. Yang, A. Mostrag-Szlichtyng, M.T.D. Cronin. Quantitative structure-skin permeability relationships. Review Article, *Toxicology*, **2017**, 387, 27-42.

IF = 3.265 (2017)

67. Stoyanova T., I. Lessigiarska, M. Mikov, **I. Pajeva**, S. Yanev. Xanthates as useful probes for testing the active sites of Cytochromes P450 4A11 and 2E1. *Frontiers in Pharmacology*, 8, **2017**, Article 672. DOI:10.3389/fphar.2017.00672

IF=3.831 (2017)

68. Al Sharif M., A. Diukendjieva-Todorova, P. Alov, V. Vitcheva, M. Mori, B. Botta, I. Tsakovska, **I. Pajeva**. Natural modulators of nonalcoholic fatty liver disease: mode of action analysis and in silico ADMET prediction, *Toxicology and Applied Pharmacology*, **2017**, 337, 45-66. DOI:10.1016/j.taap.2017.10.013.

IF = 3.616 (2017)

69. Al Sharif M., P. Alov, A. Diukendjieva, V. Vitcheva; R. Simeonova, I. Krasteva, A. Shkondrov, I. Tsakovska, **I. Pajeva**. Molecular determinants of PPAR γ partial agonism and related in silico / in

vivo studies of natural saponins as potential type 2 diabetes modulators, *Food and Chemical Toxicology*, **2018**, 112, 47-59. DOI:10.1016/j.fct.2017.12.009

IF = 3.375 (2018)

70. Diukendjieva, A., P. Alov, I. Tsakovska, T. Pencheva, A. Richarz, V. Kren, M.T.D. Cronin, **I. Pajeva**. *In vitro* and *in silico* studies of the membrane permeability of natural flavonoids from *Silybum marianum* (L.) Gaertn. and their derivatives, *Phytomedicine*, **2019**, 53, 79-85. DOI:10.1016/j.phymed.2018.09.001

IF = 4.268 (2019)

71. Al Sharif, M., V. Vitcheva, R. Simeonova, I. Krasteva, V. Manov, P. Alov, G. Popov, A. Shkondrov, **I. Pajeva**. *In silico* and *in vivo* studies of *Astragalus glycyphylloides* saponin(s) with potential relevance to metabolic syndrome modulation, *Food and Chemical Toxicology*, **2019**, 130, 317-325. DOI:10.1016/j.fct.2019.05.032

IF = 4.679 (2019)

72. Lagarde N., E. Goldwasser, T. Pencheva, D. Jereva, **I. Pajeva**, J. Rey, P. Tuffery, B.O. Villoutreix, M.A. Miteva. A free web-based protocol to assist structure-based virtual screening experiments. *International Journal of Molecular Sciences*, **2019**, 20 (18), 4648. DOI:10.3390/ijms20184648

IF=4.556 (2019)

73. Dinić J., A. Podolski-Renić, M. Jovanović, L. Musso, I. Tsakovska, **I. Pajeva**, S. Dallavalle, M. Pešić. Novel Heat Shock Protein 90 inhibitors suppress P-glycoprotein activity and overcome multidrug resistance in cancer cells. *International Journal of Molecular Sciences*, **2019**, 20, 4575. DOI:10.3390/ijms20184575

IF=4.556 (2019)

74. Dallavalle S.; V. Dobričić; L. Lazzarato; E. Gazzano; M. Machucheroe, **I. Pajeva**; I. Tsakovska, N. Zidar; R. Fruttero. Improvement of Conventional Anti-Cancer Drugs as New Tools against Resistant Tumors, *Drug Resistance Update*, **2020**, 50, 100682. DOI:10.1016/j.drug.2020.100682

IF=11.000 (2019)

75. Diukendjieva A., M. Zaharieva, M. Mori, P. Alov, I. Tsakovska, T. Pencheva, H. Najdenski, V. Kren, C. Felici, F. Bufalieri, L. Di Marcotullio, B. Botta, M. Botta, **I. Pajeva**. Dual Smo/BRAF inhibition by flavonolignans from *Silybum marianum*. *Antioxidants*, **2020**, 9(5), 384, 13 pages. DOI:10.3390/antiox9050384

IF= 5.014 (2019)

76. Dinić J., T. Efferth, A.T. García-Sosa, J. Grahovac, J. M. Padrón, **I. Pajeva**, F. Rizzolio, S. Saponara, G. Spengler, I. Tsakovska. Repurposing old drugs to fight multidrug resistant cancers, *Drug Resistance Updates*, 52, **2020**, 100713. DOI:10.1016/j.drug.2020.100713

IF=11.000 (2019)

77. Ilieva Y., L. Dimitrova, M.M.Zaharieva, M. Kaleva, P. Alov, I. Tsakovska, T. Pencheva, I. Pencheva-El Tibi, H. Najdenski, **I. Pajeva**. Cytotoxicity and microbicidal activity of commonly used organic solvents: a comparative study and application to a standardized extract from *Vaccinium Macrocarpon*, *Toxics*, **2021**, 9, 92. DOI:10.3390/toxics9050092

IF=3.271 (2019)

Статия на руски език:

78. Павлова, Й.Р., **И. К. Пъжева**, Г.Д. Велинов, О.Е. Будевски. Метод количественного определения содержания серной и фосфорной кислот в смеси. *Журн. прикл. хим.*, **1981**, LIV, 1946-1949.

IF=0.065 (1992)

II. Публикации в списания и тематични поредици със SCImago Journal Rank (SJR):

79. (1) Tsakovska, I., M. Pinto-Bazurco, **I. Pajeva**: Receptor tyrosine kinase inhibitors: QSAR and molecular modelling study, *Pharmatsija*, **2005**, 52 (3), 11-15.

SJR=0.101 (2005)

80. (2) Al Sharif M., A. Diukendjieva, P. Alov, A. Richards, M.T.D. Cronin, I. Tsakovska, **I. Pajeva**.

Optimized structure - based methodology for studying PPAR γ partial agonists. *Int.J. BIOautomation*, **2018**, 22 (1), 65-72. DOI:10.7546/ijba.2018.22.1

SJR=0.267 (2018)

81. (3) Diukendjieva A., I. Tsakovska, P. Alov, T. Pencheva, I. Pajeva, A. Worth, J. Madden, M.T.D. Cronin. Advances in the Prediction of Gastrointestinal Absorption: Quantitative Structure-Activity Relationship (QSAR) modelling of PAMPA Permeability. *Computational Toxicology*, **2019**, 10, 51-59. DOI:10.1016/j.comtox.2018.12.008

SJR=0.579 (2019)

82. (4) Jereva D., T. Pencheva, I. Tsakovska, P. Alov, **I. Pajeva**. Exploring Applicability of InterCriteria Analysis on the Performance of MOE and GOLD Scoring Functions. In: I. Georgiev et al. (eds.) *Advanced Computing in Industrial Mathematics, Studies in Computational Intelligence*, Springer, **2021**, vol. 961, 198-208. DOI: 10.1007/978-3-030-71616-5_18

SJR=0.185 (2020)

83. (5) Tsakovska I., P. Alov, N. Ikonov, V. Atanassova, P. Vassilev, O. Roeva, D. Jereva, K. Atanassov, **I. Pajeva**, T. Pencheva. InterCriteria Analysis Implementation for Exploration of the Performance of Various Docking Scoring Functions. In: Dimov I., Fidanova S. (eds) *Advances in High Performance Computing. HPC 2019. Studies in Computational Intelligence*, **2021**, vol. 902, 88-98. DOI: 10.1007/978-3-030-55347-0_8

SJR=0.185 (2020)

84. (6) Al Sharif M. P. Alov, V. Vitcheva, A. Diukendjieva, D. Aluani, V. Tzankova, **I. Pajeva**. Development of a Protocol for Virtual Screening of PPAR γ Weak Partial Agonists: Case Study on Naturally-Derived Oleanane Triterpenoids, *Int. J. BIOautomation*, **2021**, 25 (2), 117-132.

SJR=0.178 (2020)

III. Публикации в рецензирани периодични издания без IF и SJR:

В международни и чуждестранни периодични издания:

85. (1) **Pajeva, I. K.**, J.K.Seydel, L.Bock: Study of interactions between phospholipids and amphiphilic drugs active in reversing multidrug resistance in tumour cells, *Jahresbericht 1993*, Forschungszentrum Borstel, C.H.Waser, **1994**, 138-142.
86. (2) Timcheva, C., **I. Pajeva**, D.Todorov, E.Pipercova, I.Triphonova: Calcium channel blocker diltiazem as MDR-modulator, *J. Balkan Union of Oncology*, 2, **1996**, 31-35.
87. (3) **Pajeva, I.K.**, C. Globisch, R. Fleischer, M. Wiese: Structure-function relationships of P-glycoprotein and related drugs: molecular modeling study, *Actualites de Chimie Therapeutique*, **2005**, 31^e serie, 167-180.
88. (4) Tsakovska, I., I. Lessigiarska, T. Netzeva, **I. Pajeva**, A. Worth: Review of quantitative structure – activity relationships for acute mammalian toxicity, *Int. J. Bioautomation*, **2006**, 5, 90-105.
89. (5) Pencheva, T., D. Lagorce, **I. Pajeva**, B. Villoutreix, M. Miteva. AMMOS: A Software Platform for *in silico* Screening, *Int. J. Bioautomation*, **2009**, 13(4), 143-150.
90. (6) Jereva D., T. Pencheva, D. Lagorce, D. Desvillechabrol, **I. Pajeva**, M. Miteva. Post-docking optimization of protein-ligand interactions involving water molecules. *Asian Journal of Physics: Biophysics, Bioinformatics & Physical Methods in Biology and Medicine* (a special issue), **2014**, 23 (5), 745-756.

В български периодични издания:

91. (1) Павлова,Й., **И. Пъжева**: Текуща идентификация на сложни химико-технологични обекти по метода на стохастическата апроксимация, *Годишник на ЦЛА при МХП*, 1979, IV, част II, 9-15.
92. (2) Илиева,Е., Й.Павлова, **И. Пъжева**: Изследване на чувствителността на моделите, описващи процесите в дестилационна колона в содово производство, *Годишник на ЦЛА при МХП*, **1980**, V, 9-20.
93. (3) Павлова,Й., **И. Пъжева**, Г.Велинов: Нов подход при анализ на вещества с киселинно-

- основни свойства, *Годишник на ЦЛА при МХП*, **1980**, V, 147-151.
94. (4) Латева,З.Х., **И.К. Пъжева**: Модел на информационни структури за изследване на връзката между химическа структура и биологическа активност с помощта на ЕИМ, *Фармация*, **1984**, XXXIV, 5, 39-45.
 95. (5) **Пъжева, И.**: Система за прогнозиране на противотуморна активност на съединения спрямо туморни модели *in vivo*, *Онкология*, **1989**, XXVI, 1, 26-29.
 96. (6) Тодоров, Д.К., К. Тимчева, **И. Пъжева**: Лекарствена резистентност при злокачествени тумори и подходи за преодоляването и, *Онкология*, **1995**, 32 (3-4), 9-13.
 97. (7) Тимчева, К., **И. Пъжева**, Д.К. Тодоров: Лекарствена резистентност на туморите - същност, клинично значение, преодоляване, *Фармакотерапия*, **1996**, 2 (2),15-20.
 98. (8) **Пъжева, И.К.**, Л.Д.Шаламанова, И.М.Станоева: Зависимостите структура-активност при изследване на противотуморни лекарства - основни подходи и приложение, *Онкологичен преглед*, **1996**, III, 3-4, 10-14.
 99. (9) Станоева, И.М., Л.Д.Шаламанова, **Пъжева, И.К.**: Подходи на молекулярното моделиране в изследванията съединения с противотуморна активност, *Онкологичен преглед*, **1997**, IV (3), 19-24.
 100. (10) Тодоров, Д., К.Тимчева, **И.Пъжева**: Лекарствена резистентност при рака, *Съвременна медицина*, **1997**, XLVIII, 4, 3-7.
 101. (11) Атанасов,К., Л.Вайсберг, К.Гарсия, М.Даскалов, **И.Пъжева**, Р.Струб, А.Шенон, Ъ. Шоршич: Обобщени мрежи в биологията и медицината, *Списание на БАН*, **1998**, CXI, 1-2, 44-49.
 102. (12) Тимчева,К., **И. Пъжева**, Д.Тодоров: Лекарствена резистентност при злокачествени тумори – фундаментални и клинични аспекти, *Studia Onciologia*, **2000**, I (1), 9-27.
 103. (13) Лесигярска, И., **И. Пъжева**, Б. Пандова, С. Янев: QSAR и 3D QSAR анализ на серия акилксантати като инхибитори и инактиватори на цитохром Р-450 2B1, в: *Научни известия на Научно-техническия съюз по машиностроене*, **2000**, год. VII, 3(54), 150-155.
 104. (14) **Пъжева, И.**, И. Цаковска, Т. Пенчева, П. Алов, И. Лесигярска: Изследване на зависимости “структура-активност” и молекулярно моделиране на биологично активни съединения. *Списание на БАН*, **2009**, 2, 41-47.
 105. (15) **Пъжева, И.**, И. Цаковска, Т. Пенчева, П. Алов, М. Ал Шариф, И. Лесигярска, Ф. Фратев, Д. Жерева, А. Дюкенджиева. *In silico* изследвания на биологично активни молекули, *Списание на БАН*, 4, **2018**, 3-10.
 106. (16) Al Sharif M., P. Alov, I. Tsakovska, T. Pencheva, **I. Pajeva**. Estimation of structural similarity between plant-derived phenolic compounds and drug molecules by virtual screening of DrugBank, *International Scientific Journal "Machines. Technologies. Materials"*, XIV (2), **2020**, 83-86. <https://stumejournals.com/journals/mtm/2020/2/83> (отпечатано и в сборник от доклади на конференция)

IV. Публикации в рецензирани тематични поредици, книги и сборници от национални и международни научни форуми

Издадени в чужбина:

107. (1) **Pajeva, I.K.**, Z.C. Lateva, G.V. Dimitrov: SAR Oriented Database Aids Selection of Compounds for Screening, In: *Pharmacochemistry Library*, Vol.10, QSAR in Drug Design and Toxicology, D. Hadzi and B. Jerman-Blazic (Eds.), Elsevier, Amsterdam, **1987**, 49-51. [ISBN 0-444-42767-8](#)
108. (2) **Pajeva,I.K.**: Antineoplastic Activity Prediction by means of a Statistical-Heuristic Technique, In: *Progress in Clinical and Biological Research*, Vol.291, QSAR: Quantitative Structure - Activity Relationships in Drug Design, J.L.Fauchere (Ed.), Alan R. Liss, Inc., New York, **1989**, 209-212. [ISBN 0-8451-5141-X](#)
109. (3) **Pajeva, I.K.**, N.M. Neykov, P.N. Neychev: Application of a Robust Method for Detecting Outliers in Data Used for Antineoplastic Activity Prediction, In: *Trends in QSAR and Molecular Modelling* 92, C.G.Wermuth (Ed.), Escom, Leiden, **1993**, 324-325. [ISBN 10:](#)

110. (4) **Pajeva, I.K.**, J.K. Seydel: Drug-membrane interactions of some catamphiphiles: relation to the reversal of multidrug resistance in tumour cells. *Pharmazie in Unsere Zeit*, **1994**, 23 (3), 178 (Tagung der Fachgruppe Pharmazeutische Chemie der Deutschen Pharmazeutischen Gesellschaft, 7-9 March 1994, Mainz, Germany).
111. (5) **Pajeva, I.K.**, J.K. Seydel, M. Wiese: Drug-Membrane Interactions: Relationships with Multidrug Resistance Reversing Activity in Tumour Cells, In: *QSAR and Molecular Modelling: Computational Tools and Biological Applications*, F.Sanz, J. Giraldo, F.Manaut (Eds.), Prous Science Publishers, **1995**, 131-133. [ISBN 84-8124-079-6](#)
112. (6) Wiese, M., **I.K.Pajeva**: Comparative molecular field analysis of modulators of cancer multidrug resistance, In: *CHEMOMETRICS V*, J. Havel (ed.), **1999**, Masaryk University, Brno, p.161-63.
113. (7) **Pajeva, I.K.**, M. Wiese: Comparative molecular field analysis of multidrug resistance modifiers, In: *Molecular Modeling and Prediction of Bioactivity*, K. Gundertofte and F.S. Jorgensen (Eds.), Kluwer Academic / Plenum Publishers, New York, **2000**, 414-416. [ISBN 0-306-46217-6](#)
114. (8) **Pajeva, I.K.**, M. Wiese: Hydrophobic "dipole": space directionality of hydrophobicity of multidrug resistance inducers and modulators, In: "*Lipophilicity in Drug Disposition*", P.-A. Carrupt, S. Rey (Eds.), "Pharmacokinetic Optimization in Drug Research: Biological, Physicochemical and Computational Strategies. Wiley-VCH, Weinheim, **2001**, Pb04. [ISBN 3-906390-22-5](#).
115. (9) **Pajeva, I. K.**, Globisch, C., Fleischer, R., Tsakovska, I., M. Wiese: Molecular modeling of P-glycoprotein and related drugs, *Internatl. Symp. on Current Trends in Drug Discovery Research (CTDDR-2004)*, 17-20 Feb **2004**, Lucknow, India, 214-215.
116. (10) **Pajeva, I., M.** Wiese: Modeling of interactions with the multidrug resistance transporter P-glycoprotein, *Proceedings of 8th International Symposium on Pharmaceutical Sciences (ISOPS-8)*, Ankara, Turkey, 13-18 June **2006**, 61-63.
117. (11) Kacprzyk, Janusz, M. Angelova, P. Vassilev, V. Tasseva, P. Tchesmedjiev, **I. Pajeva**, K. Atanassov: On the Modelling of Genetic Networks with Generalized Nets, In: "*Issues in intuitionistic fuzzy sets and generalized nets*" . K. Atanassov, J. Kacprzyk, M. Krawczak, E. Szmidt (Eds.), **2007**, Vol. 5, Warsaw school of information technology, Warsaw, 87-96. [ISBN 978-83-88311-90-1](#)
118. (12) Tsekova, D., L. Tancheva, E. Makakova, P. Alov, **I. Pajeva**, V. Petkov. In-vivo and in-vitro activities of new L-Valine derivatives: structure-activity relationships, *Proceedings of the 30th European Peptide Symposium (30EPS)*, Helsinki, Finlandia, **2008**, 224-225.
119. (13) **Pajeva, I.** Zeit - abhängig Präsentationen der Wechselwirkungen von Arzneistoffen In: *Phänomen Zeit: Dimensionen und Strukturen in Kultur und Wissenschaft* (Dietmar Goltschnigg, Hrsg.), Stauffenburg Verlag, **2011**, 307-308. [ISBN-10: 3860570242](#)
120. (14) Fioravanzo E., A. Bassan, S. Kovarich, I. Tsakovska, **I. Pajeva**, A. Palczewska, V. Vitcheva, M.T.D. Cronin, C. Yang, A. Worth. Use of Molecular Modelling Approaches to Predict Potential Binding to Nuclear Receptors Involved in the Development of Liver Steatosis (i.e. LXR and PPAR γ). In: *Mechanism-Based Methods for Improved Toxicity Testing* (Timan Gocht and Michael Schwarz, eds.), **2015**, Vol. 5, 83-85. [ISBN: 978-2-9539634-4-1](#)

Издадени в България:

121. (1) **Pajeva, I.**, I. Tsakovska: Structure-activity relationships and molecular modeling of multidrug resistance modifiers, In: *Current trends in the development of fundamental and applied sciences*, N. Lazarov, L. Lazarov, K. Halacheva (eds.), vol.2, **1999**, p.76-82. [ISBN 954-9794-14-8](#)
122. (2) Tsakovska, I., **I. Pajeva**: Molecular modeling of new triazine derivatives as modulators of multidrug resistance, In: *Current trends in the development of fundamental and applied sciences*, N. Lazarov, L. Lazarov, K. Halacheva (eds.), vol.2, **1999**, p.83-90. [ISBN 954-9794-14-8](#)
123. (3) Lesigiarska I., **I. Pajeva**: QSAR and 3D QSAR in drug design: cytochrome P-450 inhibitors

- and antiinflammatory agents, in: *Biprocess Systems' 2001, Proceedings of 14th International Symposium and Young Scientists' School*, October 1-3 2001, Sofia, Bulgaria, **2001**, A: 17-20.
124. (4) Tsakovska I., L. Shalalmanova, **I. Pajeva**: QSAR and molecular modeling study of phenothiazines and structurally related compounds as multidrug resistance modulators, in: *Biprocess Systems' 2001, Proceedings of 14th International Symposium and Young Scientists' School*, Oct 1-3 2001, Sofia, Bulgaria, III, **2001**, 27-30.
 125. (5) Pencheva T., **I. Pajeva**, M. Miteva. Comparative Study of Different Scoring Functions for Virtual Ligand Screening, *Proceedings of International Symposium "Bioprocess Systems'2008 - BioPS'08"*, Sofia, Bulgaria, November 4-5, **2008**, II.89 - II.100.
 126. (6) Pencheva T., P. Alov, D. Jereva, **I. Pajeva**, M. A. Miteva. Post-docking Optimization and Analysis of Protein-ligand Interactions with AMMOS Free Software. In: *Topics In Chemistry And Material Science* (Eds. R.D. Nikolova, S. Simova, P. Denkova, G.N. Vayssilov), Vol. 5, Current Issues in Organic Chemistry 2, **2011**, 43–51. [ISSN 1314-0795](#)
 127. (7) Al Sharif M, P. Alov P, I. Tsakovska, I. Pajeva. In silico modelling of full PPAR γ agonists: a step towards liver steatosis risk assessment. *Series G. Medicine, Pharmacy and Dental medicine*, Union of Scientists in Bulgaria – Plovdiv, Vol. XVII, p. 182-186, **2015**. [ISSN 1311-9427](#)
 128. (8) Diukendjieva A., L. Marinov, P. Alov, I. Tsakovska, **I. Pajeva**. In silico modelling to predict transcellular permeability of bioactive compounds. *Series G. Medicine, Pharmacy and Dental medicine*, Union of Scientists in Bulgaria – Plovdiv, Vol. XVII, p. 187-190, **2015**. [ISSN 1311-9427](#)
 129. (9) Diukendjieva, A., M. Al Sharif, I. Tsakovska, T. Pencheva, P. Alov, **I. Pajeva**. In silico study of natural compounds: prediction of metabolism, toxicity and biochemical interactions. In: *Scientific reports* (Eds. R. Argirova, D. Boteva, Y. Kalvachev), Faber Publishing House, **2018**, 24-33. [ISBN 978-61900-0827-9](#)
 130. (10) Al Sharif M., P. Alov, I. Tsakovska, T. Pencheva, I. Pajeva, Estimation of structural similarity between plant-derived phenolic compounds and drug molecules by virtual screening of DrugBank, *Vth International conference high technology. Business. Society* 2020, 09-12.03.2020 – Borovets, Bulgaria, Proceedings, Year V, Issue 1 (7), Sofia, Bulgaria **2020**, 21-24. [ISSN 2535-0005](#)

V. Главни от книги

131. (1) Seydel, J.K., E.A. Coats, **I.K. Pajeva**, M. Wiese: Drug-membrane interaction and accumulation, conformation, efficacy and resistance, In: *Bioactive Compound Design: Possibilities for Industrial Use*, M.G. Ford, R. Greenwood, G.T. Brooks, R. Franke (Eds.) SCI, BIOS Sci. Publ. Ltd., Oxford, **1996**, 137-147. [ISBN 1859961657](#)
132. (2) Wiese, M., **I. Pajeva**: In silico models for interactions with transporters. In: *Comprehensive Medicinal Chemistry II*, (Editors-in-Chief: John B Taylor and David J Triggle) Vol. 5: ADMET/Property based approaches, (Eds. B. Testa, H. Waterbeemed), In silico tools in ADMET, Elsevier: Oxford, **2007**, 767-795. [ISBN: 978-0-08-045044-5](#)
133. (3) Wiese, M., **I. Pajeva**. Algorithms to predict affinity for transporters, In: *Virtual ADMET assessment in target selection and maturation*, Solvay Pharmaceuticals Conferences Series (vol. 6), B. Testa, L. Turski (Eds.), IOS Press, Amsterdam, **2006**, 187-208. [ISBN 978-1-58603-703-1](#)
134. (4) **Pajeva, I.**, M. Wiese. Application of In silico Methods to Study ABC Transporters Involved in Multidrug Resistance. In: *In silico Lead Discovery* (M. A. Miteva, Ed.), Bentham Science, **2010**, Vol. 1, 144-162. [eISBN: 978-1-60805-142-7](#)
135. (5) Pencheva, T., D. Lagorce, **I. Pajeva**, B. O. Villoutreix, M. A. Miteva, AMMOS Software: Method and Application. In: *Computational Drug Discovery and Design (Methods Mol. Biol.)* R. Baron (Ed.), Humana Press, **2012**, 819, 127-141. [ISBN-10: 1617794643](#)
SJR=0.753 (2012)
136. (6) Martiny, VY., **I. Pajeva**, M. Wiese, A.M. Davis, M. A. Miteva. Chemoinformatic and

- chemogenomic approach to ADMET. Chapter 5, Part II: Intelligent integration and extrapolation of ADMET data, In: Predictive ADMET: Integrated approaches in drug discovery and development (Eds. J. Wang and L. Urban), John Wiley & Sons, Inc., **2014**, 125-144. ISBN: [978-1-118-29992-0](#)
137. (7) Al Sharif, M., I. Tsakovska, P. Alov, V. Vitcheva, A. Diukendjieva, **I. Pajeva**. Molecular modeling approach to study the PPAR γ -ligand interactions. *Methods in Molecular Biology*, Humana, New York, NY, **2019**, 1966: 261-289. DOI: 10.1007/978-1-4939-9195-2_22. ISBN: [978-1-4939-9195-2](#)
SJR=0.597 (2019)
138. (8) **Pajeva I.**, I. Tsakovska, T. Pencheva, P. Alov, M. Al Sharif, I. Lesigiarska, D. Jereva, A. Diukendjieva. In silico studies of biologically active molecules. In: *Research in Computer Science in the Bulgarian Academy of Sciences* (Ed. K. Atanassov), Book series: *Studies in Computational Intelligence* (Ed. J. Kacprzyk), Springer, **2021**, in press. ISBN [978-3-030-72283-8](#)
SJR = 0.190 (2020)

VI. Дисертации

139. (1) **Пъжева, И.К.**: Микрокомпютърна система за изследване и прогнозиране на зависимости химическа структура - противотуморна активност при туморни модели in vivo, Дисертационен труд за присъждане на научната и образователна степен “Доктор” София, **1989**, 1-177.
140. (2) **Пъжева, И.К.**: *In silico* изследване на П-гликопротеина на множествената лекарствена резистентност при тумори, Дисертационен труд за присъждане на научната степен “Доктор на биологическите науки”, София, **2007**, 1-335.

VII. Редакции на книги (съставителство)

- (1) *Алманах на българските стипендианти/Almanach der Bulgarischen Humboldtianer*. Под редакцията на Димо Платиканов, **Илза Пъжева** и Лора Тасева/Herausgegeben von Dimo Platikanov, **Ilza Pajeva** und Lora Taseva, Craft House Bulgaria Ltd., **2011**, pp. 296. ISBN [978-954-92223-3-3](#)
- (2) *Bulgarian-German Scientific Cooperation: Past, Present, and Future*. **Ilza Pajeva**, Radka Argirova, Krum Băčvarov, Dilyana Boteva and Nikolina Burneva, Editors. Faber Publishing House, **2016**, pp. 239. ISBN [978-619-00-0517-9](#)
- (3) *25 години Хумболтов съюз в България/25 Jahre Humboldt-Union in Bulgarien/25 years Humboldt Union in Bulgaria*. Edited by **Ilza Pajeva**. Faber Publishing House, **2017**, pp. 488. ISBN [978-619-00-0677-0](#)

VIII. Други трудове, в т.ч. с публицистичен характер

- (1) **Pajeva I.K.**, Doing Research in Bulgaria and the Role of the Humboldtians: Problems and Perspectives, Diskussionspapiere der Alexander von Humboldt-Stiftung, Vertrauen verbindet – Deutschland-Alumni in der Welt von morgen, 15/**2009**, 41. (Доклад на международната конференция *Wissenswelten verbinden. Deutsche Außenpolitik für mehr Bildung, Wissenschaft und Forschung*, Berlin, Auswärtiges Amt, 19 - 20 Januar 2009. (Bonds_of_Trust_2009.de)
- (2) **Пъжева И.** Възможности за научни изследвания в Германия с програми на фондация “Александър фон Хумболт”, сп. *Наука*, **2009**, XIX, кн. 2, стр. 76.
- (3) **Пъжева И.** България има над 400 „хумболтианци“, *Аз Буки*, брой 45, 7–13. XI. **2013**, стр. 27.
- (4) **Пъжева И.** Превръщат ли се университетите в роби на икономиката? в. “Култура“, Брой

21 (2813) от 29.05.2015

- (5) **Пъжева И.**, Хр. Цветанов. Хумболтов колеж „Българо-германско научно сътрудничество: минало, настояще и бъдеще“, *Списание на БАН*, бр. 1, **2016**, 94-95.
- (6) **Пъжева И.**, Без инвестиции в науката няма прогрес, *АзБуки*, бр. 17, **2017**
- (7) Тасева Л., **И. Пъжева**. Хумболтов колегиум "Хумболтианците и научният прогрес в страните от Централна и Източна Европа". *Списание на БАН*, СХХХI, 1, 2018, 72-74.
- (8) **Пъжева И.**, Отчет на Събранието на академиците и член-кореспондентите на БАН за 2017 година, *Списание на БАН*, СХХХ, кн. 2, **2018**, 27-38.
- (9) **Пъжева И.**, Отчет на Събранието на академиците и член-кореспондентите на БАН за 2018 година, *Списание на БАН*, СХХХI, кн. 2, **2019**, 39-51.
- (10) **Пъжева И.**, Александър фон Хумболт и съвременните му последователи, *Списание на БАН*, СХХХII, кн. 5, **2019**, 46-49.
- (11) **Пъжева И.**, Отчет на Събранието на академиците и член-кореспондентите на БАН за 2019 година, *Списание на БАН*, СХХХIII, кн. 2, **2020**, 62-73.
- (12) **Пъжева И.**, Отчет на Събранието на академиците и член-кореспондентите на БАН за 2020 година, *Списание на БАН*, СХХХIV кн. 2, **2021**, 28-38.